BillionToOne, Inc.
BLLN
Rang in Aktien
#3476
BillionToOne, Inc. is a specialized diagnostics company that innovates by... BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Aktienkurs
$105.11
Marktkapitalisierung
$4.96B
Veränderung (1 Tag)
1.56%
Veränderung (1 Jahr)
-
Land
US
Handel BillionToOne, Inc. (BLLN)
Kategorie
Healthcare
P/S-Verhältnis für BillionToOne, Inc. (BLLN)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von BillionToOne, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für BillionToOne, Inc. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| Nicht genügend Daten für die angegebenen Daten. | ||
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 5.37 | - |
US
|
|
| 6.29 | - |
US
|
|
| 21.02 | - |
US
|
|
| - | - |
CN
|
|
| 6.67 | - |
US
|
